Expect near-term stock pressure as the ATM is drawn down; watch daily volume and price action for accelerated selling. The overhang will persist until the full $200M is utilized or the ATM is terminated. No fundamental catalyst offsets this dilution.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $31.67entry
- T+1 · 3mo ago +0.82%α +1.02% · $31.93
- T+5 · 3mo ago +4.07%α +4.17% · $32.96
- T+20 · 3mo ago −2.46%α −1.22% · $30.89
- T+60 · 20d ago −17.49%α −17.28% · $26.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stoke Therapeutics filed a prospectus supplement to sell up to $200 million of common stock in an at-the-market (ATM) offering through Cantor Fitzgerald. At a $1.8B market cap, this represents ~11% potential dilution, creating near-term selling pressure and a clear negative signal for existing shareholders.
Key Facts
- On August 3, 2026, Stoke filed a prospectus supplement under its existing Sales Agreement with Cantor Fitzgerald for an ATM offering of up to $200 million in common stock.
- The offering is made under the Company's automatic shelf registration statement on Form S-3ASR (File No. 333-294402) filed March 18, 2026.
- Shares may be sold from time to time at market prices, with no fixed timetable or minimum price.
Financial Impact
Up to $200M in new equity, equivalent to ~11% of the $1.8B market cap, resulting in material dilution to existing shareholders.
Risk Factors
- Dilution of ~11% if the full $200M is issued at current prices
- Ongoing overhang from continuous ATM sales may cap upside
- Possible negative signal to market about near-term cash needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-330804 |
| Document: d135735dex51.htm | 0001193125-26-330804 |
| Document: 0001193125-26-330804-index-headers.html | 0001193125-26-330804 |
| Document: 0001193125-26-330804-index.html | 0001193125-26-330804 |
| Document: 0001193125-26-330804.txt | 0001193125-26-330804 |
Track record
18 reports on STOK
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers